NDI Medical

NDI relies on proprietary platform technologies — implantable pulse generators, leads, and surgical tools — that it adapts to multiple therapeutic applications. It sources invention opportunities through formal partnerships with the Cleveland FES Center, Case Western Reserve University, Cleveland Clinic, MetroHealth Medical Center, and Duke University. The firm’s research and development teams work directly with clinician end-users to shape products toward unmet clinical needs.

NDI describes itself as a hybrid venture capital and commercialization firm. It deploys capital through the NDI Healthcare Fund, but unlike a traditional fund manager it builds companies on top of its own shared IP and engineering platform. This means the firm takes an active role in product development, regulatory work, and commercial launch — not just board-level oversight.

NDI focuses on early-stage neurodevice companies, typically from concept through first commercial exit. According to the firm’s own disclosures, the NDI Healthcare Fund has raised $26 million, split between private equity ($17 million) and non-dilutive grant and loan capital ($9 million) from sources including the NIH, U.S. Department of Defense, and Ohio’s Third Frontier Program. The firm blends equity investment with operating support through its shared-services model.

The firm’s most prominently cited exit is the sale of its first portfolio company to Medtronic Inc. in April 2008 for $42 million, which it states returned over 150 times the original investment to investors. Beyond that, NDI has not publicly disclosed additional exit names or aggregate realized returns.

NDI invests exclusively in neurodevice technologies — stimulators, leads, surgical equipment, and associated software — targeting conditions such as chronic pain, Parkinson’s disease, depression, epilepsy, obesity, and stroke. It does not invest in pharmaceuticals, biologics, or non-device healthcare services. The firm’s stated focus is entirely on neuromodulation and neurostimulation.

NDI co-founded the Ohio Neurostimulation and Neuromodulation Partnership with Case Western Reserve University, Cleveland Clinic, and MetroHealth Medical Center. It also works with the Cleveland Functional Electrical Stimulation Center, one of the world’s leading neurotech research hubs. These relationships give NDI structured access to clinician-inventors and early-stage device concepts before they reach the broader venture market.

The firm has not publicly disclosed its investor base or ownership structure. The NDI Healthcare Fund’s disclosed $17 million in private equity suggests it raises capital from external backers, but the identity and concentration of those limited partners remain private. The firm has also drawn significant non-dilutive funding from federal and state grant programs.